These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21401356)

  • 1. Enhanced peritubular capillary flow and renal function can be accomplished in normoalbuminuric type 2 diabetic nephropathy.
    Futrakul N; Kulaputana O; Futrakul P; Chavanakul A; Deekajorndech T
    Ren Fail; 2011; 33(3):312-5. PubMed ID: 21401356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal microvascular disease predicts renal function in diabetes.
    Futrakul N; Futrakul P
    Ren Fail; 2012; 34(1):126-9. PubMed ID: 22010784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered vascular homeostasis in type 2 diabetic nephropathy.
    Futrakul N; Butthep P; Futrakul P
    Ren Fail; 2009; 31(3):207-10. PubMed ID: 19288326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adequate vascular repair is relevant to improving renal perfusion and function following vasodilators in normoalbuminuric type 2 diabetic nephropathy.
    Futrakul N; Futrakul P
    Am J Kidney Dis; 2009 Sep; 54(3):583-4. PubMed ID: 19700066
    [No Abstract]   [Full Text] [Related]  

  • 5. Early detection of endothelial injury and dysfunction in conjunction with correction of hemodynamic maladjustment can effectively restore renal function in type 2 diabetic nephropathy.
    Futrakul N; Butthep P; Vongthavarawat V; Futrakul P; Sirisalipoch S; Chaivatanarat T; Suwanwalaikorn S
    Clin Hemorheol Microcirc; 2006; 34(3):373-81. PubMed ID: 16614461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubular dysfunction and hemodynamic alteration in normoalbuminuric type 2 diabetes.
    Futrakul N; Vongthavarawat V; Sirisalipotch S; Chairatanarat T; Futrakul P; Suwanwalaikorn S
    Clin Hemorheol Microcirc; 2005; 32(1):59-65. PubMed ID: 15665427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE-inhibition and renoprotection in early diabetic nephropathy. Response to enalapril acutely and in long-term combination with conventional antihypertensive treatment.
    Pedersen MM; Christensen CK; Hansen KW; Christiansen JS; Mogensen CE
    Clin Invest Med; 1991 Dec; 14(6):642-51. PubMed ID: 1665407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of endothelial dysfunction and early therapeutic correction effectively restore renal function in type 2 diabetic nephropathy.
    Futrakul N; Butthep P
    Ren Fail; 2005; 27(4):493-4. PubMed ID: 16060141
    [No Abstract]   [Full Text] [Related]  

  • 9. Improvement of renal function in type 2 diabetic nephropathy.
    Futrakul N; Butthep P; Futrakul P; Sitprija V
    Ren Fail; 2007; 29(2):155-8. PubMed ID: 17365929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of flutamide on systemic and renal hemodynamics in Zucker diabetic rats: paradoxic renal vasodilator response to endothelin-1 and TXA2 receptor activation in female sex.
    Ajayi AA; Fidelis P
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):191-8. PubMed ID: 17110800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy.
    Aggarwal HK; Jain D; Talapatra P; Yadav RK; Gupta T; Kathuria KL
    Ren Fail; 2010; 32(8):941-6. PubMed ID: 20722561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
    Remuzzi G; Macia M; Ruggenenti P
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S90-7. PubMed ID: 16565256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
    Steinke JM; Mauer M;
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease.
    Casey RG; Joyce M; Roche-Nagle G; Chen G; Bouchier-Hayes D
    J Surg Res; 2005 Feb; 123(2):176-81. PubMed ID: 15680375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of diabetic nephropathy. Effects of ACE inhibition on microcirculation].
    Haak T; Haak E; Jungmann E; Kusterer K; Usadel KH
    Fortschr Med; 1997 Dec; 115(35-36):26-9. PubMed ID: 9499637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered vascular homeostasis in chronic kidney disease.
    Futrakul N; Butthep P; Futrakul P
    Clin Hemorheol Microcirc; 2008; 38(3):201-7. PubMed ID: 18239262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.